Experimental CF Compound ETX001 Shows Promise in Preclinical Studies
Enterprise’s investigational ETX001 shows promise in a preclinical study and could be a potential therapy for all CF patients, regardless of CFTR mutation. Read more about it here.
What are your thoughts on this news?
Sorry, there were no replies found.
Log in to reply.